New treatments
miDiagnostics announces collaboration with Galapagos to develop closed-flow, ultra-rapid CAR-T sterility test for its point-of-care CAR-T manufacturing platform
Leuven, Belgium, November 10, 2023 – miDiagnostics NV, a global technology leader in point-of-care diagnostics, today announced a collaboration agreement […] November 10, 2023 · Quality by Design - Business & Communications
Pharmaceutical market access: how real-world data fuel better health beyond clinical trials
Studies of a drug’s effectiveness and safety don’t end with clinical trials – they extend beyond market access when the […] September 27, 2023 · Janssen Pharmaceutica
V-Bio Ventures portfolio company Orionis Biosciences announces collaboration with Genentech to discover and develop molecular glue class medicines
September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated […] September 20, 2023 · V-Bio VenturesAugustine Therapeutics expands its leadership team and R&D platform, enters regulatory development.
Leuven, Belgium, September 12th, 2023 – Augustine Therapeutics, a biotech company developing innovative therapies for neuromuscular and neurodegenerative disorders, announced […] September 12, 2023 · Quality by Design - Business & CommunicationsV-Bio Ventures portfolio company Corteria Pharmaceuticals raises EUR 65 million to advance its transformational medicines for cardiovascular diseases
Ghent, Belgium, 7 September 2023 – Corteria Pharmaceuticals, a V-Bio Ventures portfolio company, is a biopharmaceutical company specialized in the […] September 7, 2023 · V-Bio Ventures
The obesity revolution: will new drugs bring about big changes?
The recent approval of the obesity and diabetes drugs Wegovy, Ozempic, and Mounjaro has brought about big headlines, but are […] June 21, 2023 · V-Bio VenturesV-Bio Ventures portfolio company Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic
Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its […] May 15, 2023 · V-Bio Ventures
University Hospital Ghent and VIB are testing medication to treat COVID-19-associated respiratory illness
University Hospital Ghent and VIB are assessing a drug called Leukine® to treat patients with respiratory illness associated with COVID-19. Major medical centers in [...] March 25, 2020 · BioVox
Belgian clinical trials for COVID-19
With COVID-19 cases soaring into the millions, and a vaccine still a ways off, patients are desperate for a treatment. […] May 5, 2020 · BioVox
Cell therapies: opportunities and challenges
Recent activities in the cell therapy field have prompted many investment funds to pour fresh and increasing capital into this […] May 5, 2020 · V-Bio Ventures
Fundamental research leads to treatment breakthrough in rare genetic diseases
A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing […] June 8, 2020 · BioVox